BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting
BioCryst Pharmaceuticals, Inc. (BCRX)
Last biocryst pharmaceuticals, inc. earnings: 3/5 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
biocryst.gcs-web.com/investor-relations
Company Research
Source: GlobeNewswire
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present an abstract including results from the ZENITH-1 study at the upcoming annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) February 22-25 in San Francisco. Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial; Session 2209, Urticaria and Angioedema, Poster 110, Moscone Center South, Exhibition Level, Hall B, Saturday, February 23, 9:45 a.m. PT About BioCryst Pharmaceuticals BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including BCX7353, an oral treatment fo
Show less
Read more
Impact Snapshot
Event Time:
BCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCRX alerts
High impacting BioCryst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
BCRX
News
- With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing [Yahoo! Finance]Yahoo! Finance
- BioCryst to Report First Quarter 2024 Financial Results on May 6GlobeNewswire
- BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyGlobeNewswire
- Pint Pharma Announces the Approval of ORLADEYO® (berotralstat), the First Oral Therapy Indicated for Preventing Hereditary Angioedema (HAE) Attacks in Adult and Pediatric Patients Aged 12 and Older in Brazil [Yahoo! Finance]Yahoo! Finance
- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
BCRX
Earnings
- 2/26/24 - Miss
BCRX
Sec Filings
- 4/2/24 - Form 4
- 3/4/24 - Form 4
- 3/4/24 - Form 4
- BCRX's page on the SEC website